Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-15T11:42:48.039Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1545 - Functional Outcomes with Once-monthly Paliperidone Palmitate in Acute and in Non-acute Patients with Schizophrenia Previously Unsuccessfully Treated with Oral Antipsychotics

Published online by Cambridge University Press:  15 April 2020

L. Hargarter ,
P. Bergmans ,
P. Cherubin ,
A. Björner ,
R. Knegtering ,
E. Parellada ,
B. Carpiniello ,
P. Vidailhet ,
C. Mertens  and
A. Schreiner
L. Hargarter
Affiliation:
EMEA MAF, Janssen-Cilag GmbH, Neuss, Germany
P. Bergmans
Affiliation:
Biostatistics & Programming, Janssen Cilag Benelux, Tilburg, Netherlands
P. Cherubin
Affiliation:
EMEA MAF, Janssen Cilag France, Issy-les-Moulineaux, France
A. Björner
Affiliation:
Psychiatry, Psykosmottagningen, Mölndal, Sweden
R. Knegtering
Affiliation:
Psychiatry, University Medical Center of Groningen, Groningen, Netherlands
E. Parellada
Affiliation:
Psychiatry, Hospital Clinic de Barcelona, Barcelona, Spain
B. Carpiniello
Affiliation:
Psychiatry, Clininca Psichiatrica Università di Cagliari, Cagliari, Italy
P. Vidailhet
Affiliation:
Psychiatry, Centre Hospitalier Régional Universitaire Strasbourg, Strasbourg, France
C. Mertens
Affiliation:
Psychiatry, Neuro- Psychiatrische Kliniek St-Camillu, Sint Denijs Westrem, Belgium
A. Schreiner
Affiliation:
EMEA MAF, Janssen-Cilag GmbH, Neuss, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Effective antipsychotic treatment of schizophrenia should, beyond symptom control, translate into meaningful functional improvements. This study explored functional outcomes in patients with schizophrenia switched from previous unsuccessful treatment with oral antipsychotics to flexible doses of paliperidone palmitate (PP).

Methods

Two groups of acute (N=212) and non-acute (N=593) patients from an international prospective open-label 6-month study. Outcomes were change in Positive and Negative Syndrome Scale (PANSS) total score, Personal and Psychosocial Performance scale (PSP) and Mini International Classification of Functionality, Disability and Health Rating for Activity and Participation Disorders in Psychological Illnesses (Mini-ICF-APP).

Results

Both groups significantly improved from baseline to endpoint in mean PANSS total score from 98.5±20.1 to 67.4±24.0 (mean change -31.0±29.0) in acute and from 71.5±14.6 to 59.7±18.1 (mean change -11.7±15.9) in non-acute patients (all p<0.0001). Patient functioning in PSP total score increased from 43.9±15.0 at baseline to 62.9±17.1 at endpoint (mean change 19.0±18.7; 95% confidence interval [CI] 16.4;21.6) in the acute and from 58.1±13.4 at baseline to 66.1±15.7 at endpoint (mean change 8.0±14.0; 95%CI 6.8;9.1) in the non-acute group (both groups p<0.0001). Illness-related disabilities of activity and participation within groups improved significantly in Mini-ICF-APP global score decreasing from 26.8±8.5 to 18.5±9.8 (mean change -8.0±10.4; 95%CI -9.5;-6.5) in acute and from 19.8±7.9 to 15.9±8.8 (mean change: -4.0±7.5; 95%CI - 4.6;-3.3) from baseline to endpoint in non-acute patients (both groups p<0.0001).

Conclusions

Symptom reduction in acute and non-acute patients with schizophrenia treated with PP after previous unsuccessful treatment with oral antipsychotics was associated with clinically meaningful functional improvements.

Type
E08 - e-Poster Oral Session 08: Schizophrenia, Affective disorders, Addiction
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.